Thus, we propose that the established KRAS-initiated pancreatic cancer model, generated by use of the combination of CRE/Lox and GAL4/UAS systems, now provides a preclinical platform to test various strategies for pancreatic cancer and finally improve outcomes for pancreatic cancer patients. The gene discussed is KRAS; the disease is pancreatic neoplasm.